Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States

L Howard1, M Ament, C R Fleming

  • 1Department of Medicine, Albany Medical College, New York, USA.

Gastroenterology
|August 1, 1995

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Health Sciences
  • Health Services And Systems
  • Family Care
  • Current Use And Clinical Outcome Of Home Parenteral And Enteral Nutrition Therapies In The United States

    • Home parenteral and enteral nutrition (HPEN) use doubled in the US, with therapy being safe and effective. Quality survival, not diagnosis, justifies HPEN, especially for patients with short-term prognoses.

    Area of Science:

    • Clinical Nutrition
    • Health Services Research

    Background:

    • Home nutrition support, particularly parenteral nutrition, incurs significant costs.
    • Understanding current usage and outcomes of home parenteral and enteral nutrition (HPEN) is crucial.

    Purpose of the Study:

    • To examine the current usage patterns of HPEN in the United States.
    • To evaluate the quality of therapy outcomes associated with HPEN.

    Main Methods:

    • Analysis of Medicare HPEN utilization from 1989 to 1992, focusing on use, growth, and costs.
    • Assessment of disease distribution and therapy outcomes using National Registry data from 9288 HPEN patients (1985-1992).

    Main Results:

    • US HPEN prevalence was 4-10 times higher than in other Western nations, with usage doubling between 1989-1992.
    • Approximately 40,000 parenteral and 152,000 enteral home patients were recorded in 1992.
    • HPEN therapies demonstrated relative safety, with primary disease significantly impacting survival and rehabilitation; age was not a barrier.

    Conclusions:

    • Predicted quality survival at home for several months is a stronger justification for HPEN than a specific diagnosis.
    • Further evaluation is needed for HPEN's role in terminal conditions and in patients lacking primary gastrointestinal diseases.

    Related Experiment Videos